Physician

Andrew Ayars, MD

According to 2025 Medicare claims, Andrew Ayars, MD (NPI: 1336286608) practices allergy/immunology in the Bellingham, WA market, with the plurality of this provider's patient population coming from Whatcom, WA. This provider's primary affiliated billing organization is BELLINGHAM ASTHMA ALLERGY IMMUNOLOGY CLINIC PS (NPI: 1174672281; TIN: 912083521) and primary practice location at 98225-1946.

Ayars' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 275 traditional Medicare patients, billed 9,956 HCPCS/CPT codes, and received $182,390 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 676 prescription claims across 178 beneficiaries totaling $268,558 in drug costs, led by Dupixent Syringe (Dupilumab). DME data shows 100 claims. Open Payments data shows 23 records totaling $569. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $22,652 and ending at $182,390. Concurrently, Part D prescription costs have risen steadily, from $52,763 to $268,558. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	115	1,330	$22,652
2016	120	2,905	$61,812
2017	120	986	$18,675
2018	139	1,464	$25,185
2019	134	1,028	$20,960
2020	103	578	$15,700
2021	140	1,042	$23,179
2022	117	815	$20,495
2023	214	2,654	$53,613
2024	275	9,956	$182,390

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	76	365	$52,763
2016	74	343	$440,754
2017	76	344	$147,109
2018	106	491	$211,927
2019	102	480	$270,126
2020	98	594	$373,859
2021	119	688	$727,825
2022	116	798	$1,324,536
2023	156	824	$1,488,402
2024	178	676	$268,558

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	81	$124,049
2016	N/R	97	$201,704
2017	N/R	131	$155,881
2018	N/R	185	$193,628
2019	N/R	242	$285,514
2020	N/R	415	$570,988
2021	N/R	369	$541,870
2022	11	389	$612,256
2023	N/R	289	$487,531
2024	N/R	100	$102,770

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	111	111	$119
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	157	220	$86
94375	Test to measure rate of airflow	85	98	$27
95012	Test to measure the level of nitric oxide gas	78	87	$14
95004	Test for allergy using allergenic extract	86	2,000	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Dupixent Syringe	Dupilumab	16	532	$65,869
Advair Hfa	Fluticasone Propion/Salmeterol	38	1,140	$16,011
Cromolyn Sodium	Cromolyn Sodium	37	1,152	$13,873
Spiriva Respimat	Tiotropium Bromide	19	690	$8,324
Qvar Redihaler	Beclomethasone Dipropionate	11	540	$4,704

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	17	$65,992
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	N	N/R	13	$30,150
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	13	$4,285
J7626	Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg	N	N/R	15	$958
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	11	$772

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	23	$569	GENZYME CORPORATION
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Andrew Ayars, MD?

Tedicare shows public-source Medicare data for Andrew Ayars, MD (NPI 1336286608), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrew Ayars, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Andrew Ayars, MD?

Andrew Ayars, MD is linked to BELLINGHAM ASTHMA ALLERGY IMMUNOLOGY CLINIC PS (billing NPI 1174672281) in the available physician profile data.

Does Andrew Ayars, MD have Open Payments data?

Andrew Ayars, MD has 23 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.